Shield Therapeutics has announced that its partner in China, ASK, expects to submit the file for marketing authorisation to the China regulator (NMPA) – including the recently approved US pediatric Phase 3 data – for the approval for ACCRUFeR® in 1Q26. Shield and ASK have also agreed to amend terms of the China License Agreement: Shield will now receive a development milestone of $7.9m by 31 January 2026 and a pricing milestone of up to $3m based on the reimbursed price in China, replacing the o ....
